Assertio Therapeutics (ASRT) Misses Q4 EPS by 99c
Tweet
Share
E-mailGet Alerts ASRT Hot Sheet
Join SI Premium – FREE
Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($1.06), $0.99 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $28.36 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Metalla Royalty & Streaming Ltd. (MTA) Reports In-Line Q2 EPS
- Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
